SMOKING STATUS AFFECTING SURVIVAL OF ADENOCARCINOMA LUNG CANCER PATIENTS IN KUALA LUMPUR, MALAYSIA

Nida Sajid Ali Bangash; Natasha Hashim; Nahlah Elkudssiah Ismail

doi:10.22159/ajpcr.2017.v10i9.17147

Authors

Nida Sajid Ali Bangash Clinical BioPharmaceutics Research Group (CBRG), Department of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia
Natasha Hashim Department of Oncology and Radiotherapy, Hospital Kuala Lumpur, 50300 Kuala Lumpur, Malaysia
Nahlah Elkudssiah Ismail Dean's office, Faculty of Pharmacy, MAHSA University, Jalan SP2, Bandar Saujana Putra, 42610 Jenjarom kuala Langat, Selangor

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i9.17147

Keywords:

Adenocarcinoma, Smokers, Survival

Abstract

Â

Â Objective: Adenocarcinoma (AC) of the lung is now the most common histologic type of non-small cell lung cancer (NSCLC) worldwide since the past 20 years. This study was conducted to investigate survival difference among smoker and non-smoker lung AC patients.

Methods: A retrospective observational study was conducted for 81 advanced NSCLC adult Malaysian patients in Radiotherapy and Oncology Clinic at Hospital Kuala Lumpur, Malaysia. A total of adult 30 Malaysian smokers and 51 non-smokers with lung AC were included. Ex-smokers were not included in the study. Demographic and clinical data were collected and described. For survival analysis, Kaplanâ€“Meier test and log-rank test were used to calculate overall survival (OS) and analyse the difference in the survival curve. Cox proportional hazard model was used to identify prognostic significance of smoking status.

Results: Non-smokers showed a significant association with female gender and Stage IV NSCLC. The median OS was higher for non-smokers (493 days) as compared to smokers (230 days). The Cox proportional hazard model showed higher hazard ratio for smokers.

Conclusion: Non-smoking is an independent positive prognostic factor in lung AC.

Downloads

Download data is not yet available.

References

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52(1):23-47.

Carbone D. Smoking and cancer. Am J Med 1992;93 Suppl 1:13-7.

Parkin DM, Sasco AJ. Lung cancer: Worldwide variation in occurrence and proportion attributable to tobacco use. Lung Cancer 1993;9(1-6):1-16.

NSCLC: A Guide for Patients-Information based on ESMO Clinical Practice Guidelines. European Society for Medical Oncology (ESMO); 2014. Available from: http://www.esmo.org/EN-Non-Small-Cell-Lung-Cancer-Guide-for-Patients. [Last cited on 2016 Jan 11].

Franceschi S, Bidoli E. The epidemiology of lung cancer. Ann Oncol 1999;10 Suppl 5:S3-6.

Kreuzer M, Kreienbrock L, MÃ¼ller KM, Gerken M, Wichmann E. Histologic types of lung carcinoma and age at onset. Cancer 1999;85(9):1958-65.

Hoffmann D, Rivenson A, Hecht SS. The biological significance of tobacco-specific N-nitrosamines: Smoking and adenocarcinoma of the lung. Crit Rev Toxicol 1996;26(1):199-211.

Wynder EL, Goodman MT. Smoking and lung cancer: Some unresolved issues. Epidemiol Rev 1983;5(1):177-207.

Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, et al. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol 2013;8(6):753-8.

Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs. Current smokers with primary adenocarcinoma of the lung. Chest 2004;126(2):347-51.